Skip to Main Content

Advertisement intended for health care professionals

Umbrella Alt Text
Cart
header search
Search
Skip Nav Destination

Issue Archive

Volume 3, Issue 9
May 14 2019
Issue Cover

Table of Contents

CLINICAL TRIALS AND OBSERVATIONS

Favorable outcomes with de-escalated radiation therapy for limited-stage nodular lymphocyte-predominant Hodgkin lymphoma
Clinical Trials & Observations
Chelsea C. Pinnix,Sarah A. Milgrom,Chan Yoon Cheah,Jillian R. Gunther,Ethan B. Ludmir,Christine F. Wogan,Loretta J. Nastoupil,Sattva S. Neelapu,Jason Westin,Hun J. Lee,Swaminathan P. Iyer,Raphael E. Steiner,Luis E. Fayad,Nathan H. Fowler,Michael L. Wang,Felipe Samaniego,Maria A. Rodriguez,Amy E. Rich,L. Jeffrey Medeiros,Bouthaina S. Dabaja
View Articletitled, Favorable outcomes with de-escalated radiation therapy for limited-stage nodular lymphocyte-predominant Hodgkin lymphoma
Brentuximab vedotin followed by bendamustine supercharge for refractory or relapsed Hodgkin lymphoma
Clinical Trials & Observations
M. Picardi,R. Della Pepa,C. Giordano,N. Pugliese,C. Mortaruolo,F. Trastulli,M. G. Rascato,I. Cappuccio,M. Raimondo,M. Memoli,M. Monteverde,M. Mascolo,F. Pane
View Articletitled, Brentuximab vedotin followed by bendamustine supercharge for refractory or relapsed Hodgkin lymphoma
Acalabrutinib monotherapy in patients with chronic lymphocytic leukemia who are intolerant to ibrutinib
Clinical Trials & Observations
Farrukh T. Awan,Anna Schuh,Jennifer R. Brown,Richard R. Furman,John M. Pagel,Peter Hillmen,Deborah M. Stephens,Jennifer Woyach,Elena Bibikova,Prista Charuworn,Melanie M. Frigault,Ahmed Hamdy,Raquel Izumi,Bolan Linghu,Priti Patel,Min Hui Wang,John C. Byrd

The introduction of the Bruton tyrosine kinase (BTK) inhibitor ibrutinib revolutionized the treatment of chronic lymphocytic leukemia. However, because inefficacy or intolerable side effects, some patients do not benefit. Acalabrutinib is a covalent BTK inhibitor with greater selectivity than ibrutinib. Byrd and colleagues explored acalabrutinib in patients refractory to or intolerant of ibrutinib, finding exciting evidence for efficacy and tolerability.

View Articletitled, Acalabrutinib monotherapy in patients with chronic lymphocytic leukemia who are intolerant to ibrutinib

LYMPHOID NEOPLASIA

Childhood use of antimicrobials and risk of Hodgkin lymphoma: a Danish register–based cohort study
Clinical Trials & Observations
Henrik Hjalgrim,Signe Holst Søegaard,Lisa Lyngsie Hjalgrim,Klaus Rostgaard
View Articletitled, Childhood use of antimicrobials and risk of Hodgkin lymphoma: a Danish register–based cohort study
Efficacy and predictors of response of lenalidomide and rituximab in patients with treatment-naive and relapsed CLL
Clinical Trials & Observations
Paolo Strati,Koichi Takahashi,Christine B. Peterson,Michael J. Keating,Philip A. Thompson,Naval G. Daver,Nitin Jain,Jan A. Burger,Zeev Estrov,Susan M. O'Brien,Hagop M. Kantarjian,William G. Wierda,P. Andrew Futreal,Alessandra Ferrajoli
View Articletitled, Efficacy and predictors of response of lenalidomide and rituximab in patients with treatment-naive and relapsed CLL

MYELOID NEOPLASIA

Myeloid translocation gene CBFA2T3 directs a relapse gene program and determines patient-specific outcomes in AML
Nickolas Steinauer,Chun Guo,Chunfa Huang,Madeline Wong,Yifan Tu,Carl E. Freter,Jinsong Zhang
View Articletitled, Myeloid translocation gene CBFA2T3 directs a relapse gene program and determines patient-specific outcomes in AML
Supplemental data
Critical role of Jumonji domain of JMJD1C in MLL-rearranged leukemia
Jesus Izaguirre-Carbonell,Luke Christiansen,Robert Burns,Jesse Schmitz,Chenxuan Li,Rebekah L. Mokry,Theresa Bluemn,Yongwei Zheng,Jian Shen,Karen-Sue Carlson,Sridhar Rao,Demin Wang,Nan Zhu
View Articletitled, Critical role of Jumonji domain of JMJD1C in MLL-rearranged leukemia
Supplemental data
Clinicopathologic and genetic characterization of nonacute NPM1-mutated myeloid neoplasms
Clinical Trials & Observations
Sanjay S. Patel,Caleb Ho,Ryan N. Ptashkin,Sam Sadigh,Adam Bagg,Julia T. Geyer,Mina L. Xu,Thomas Prebet,Emily F. Mason,Adam C. Seegmiller,Elizabeth A. Morgan,David P. Steensma,Eric S. Winer,Waihay J. Wong,Robert P. Hasserjian,Olga K. Weinberg
View Articletitled, Clinicopathologic and genetic characterization of nonacute <em>NPM1</em>-mutated myeloid neoplasms

PLATELETS AND THROMBOPOIESIS

Generation of transgenic zebrafish with 2 populations of RFP- and GFP-labeled thrombocytes: analysis of their lipids
Weam Fallatah,Imesha W. De Silva,Guido F. Verbeck,Pudur Jagadeeswaran
View Articletitled, Generation of transgenic zebrafish with 2 populations of RFP- and GFP-labeled thrombocytes: analysis of their lipids
Supplemental data
Dysregulated megakaryocyte distribution associated with nestin+ mesenchymal stem cells in immune thrombocytopenia
Min Wang,Ru Feng,Jia-min Zhang,Lin-lin Xu,Fei-er Feng,Chen-cong Wang,Qian-ming Wang,Xiao-lu Zhu,Yun He,Jing Xue,Hai-xia Fu,Meng Lv,Yuan Kong,Ying-jun Chang,Lan-ping Xu,Kai-yan Liu,Xiao-jun Huang,Xiao-hui Zhang
View Articletitled, Dysregulated megakaryocyte distribution associated with nestin<sup>+</sup> mesenchymal stem cells in immune thrombocytopenia
Supplemental data

RED CELLS, IRON, AND ERYTHROPOIESIS

Hyperfiltration predicts long-term renal outcomes in humanized sickle cell mice
Malgorzata Kasztan,Brandon M. Fox,Jeffrey D. Lebensburger,Kelly A. Hyndman,Joshua S. Speed,Jennifer S. Pollock,David M. Pollock
View Articletitled, Hyperfiltration predicts long-term renal outcomes in humanized sickle cell mice
Height-corrected low bone density associates with severe outcomes in sickle cell disease: SCCRIP cohort study results
Clinical Trials & Observations
Oyebimpe O. Adesina,James G. Gurney,Guolian Kang,Martha Villavicencio,Jason R. Hodges,Wassim Chemaitilly,Sue C. Kaste,Babette S. Zemel,Jane S. Hankins
View Articletitled, Height-corrected low bone density associates with severe outcomes in sickle cell disease: SCCRIP cohort study results
Supplemental data
Phthalides serve as potent modulators to boost fetal hemoglobin induction therapy for β-hemoglobinopathies
Wei-Ren Chen,Chia-Cheng Chou,Chia C. Wang
View Articletitled, Phthalides serve as potent modulators to boost fetal hemoglobin induction therapy for β-hemoglobinopathies
Supplemental data

THROMBOSIS AND HEMOSTASIS

Infused factor VIII–expressing platelets or megakaryocytes as a novel therapeutic strategy for hemophilia A
Randolph B. Lyde,Hyun Sook Ahn,Karen K. Vo,Danuta J. Jarocha,John Tkaczynski,Elsa Treffeisen,Spencer K. Sullivan,Rodney M. Camire,Denise E. Sabatino,Deborah L. French,Mortimer Poncz
View Articletitled, Infused factor VIII–expressing platelets or megakaryocytes as a novel therapeutic strategy for hemophilia A
Supplemental data
Peptides identified on monocyte-derived dendritic cells: a marker for clinical immunogenicity to FVIII products
Wojciech Jankowski,Yara Park,Joseph McGill,Eugene Maraskovsky,Marco Hofmann,Vincent P. Diego,Bernadette W. Luu,Tom E. Howard,Roberta Kellerman,Nigel S. Key,Zuben E. Sauna
View Articletitled, Peptides identified on monocyte-derived dendritic cells: a marker for clinical immunogenicity to FVIII products
Supplemental data
Structural basis of the leukocyte integrin Mac-1 I-domain interactions with the platelet glycoprotein Ib
Juliet Morgan,Muhammad Saleem,Ruiqi Ng,Caroline Armstrong,Szu S. Wong,Simon G. Caulton,Alice Fickling,Huw E. L. Williams,Adam D. Munday,José A. López,Mark S. Searle,Jonas Emsley
View Articletitled, Structural basis of the leukocyte integrin Mac-1 I-domain interactions with the platelet glycoprotein Ib
Supplemental data
Predictors of relapse and efficacy of rituximab in immune thrombotic thrombocytopenic purpura
Clinical Trials & Observations
Lova Sun,Johnathan Mack,Ang Li,Justine Ryu,Vivek A. Upadhyay,Lynne Uhl,Richard M. Kaufman,Christopher P. Stowell,Walter S. Dzik,Robert S. Makar,Pavan K. Bendapudi
View Articletitled, Predictors of relapse and efficacy of rituximab in immune thrombotic thrombocytopenic purpura
Supplemental data
Elimination of the fibrinogen integrin αMβ2-binding motif improves renal pathology in mice with sickle cell anemia
Md Nasimuzzaman,Paritha I. Arumugam,Eric S. Mullins,Jeanne M. James,Katherine VandenHeuvel,Marilou G. Narciso,Maureen A. Shaw,Sarah McGraw,Bruce J. Aronow,Punam Malik
View Articletitled, Elimination of the fibrinogen integrin α<sub>M</sub>β<sub>2</sub>-binding motif improves renal pathology in mice with sickle cell anemia
Supplemental data

TRANSPLANTATION

Antirelapse effect of pretransplant exposure to rabbit antithymocyte globulin
Clinical Trials & Observations
Rosy Dabas,Kareem Jamani,Shahbal B. Kangarloo,Poonam Dharmani-Khan,Tyler S. Williamson,Samar Ousia,Caylib Durand,Don Morris,Douglas Mahoney,Lynn Savoie,Ahsan Chaudhry,Victor H. Jimenez-Zepeda,Faisal M. Khan,Andrew Daly,Jan Storek
View Articletitled, Antirelapse effect of pretransplant exposure to rabbit antithymocyte globulin
Supplemental data
GRFS and CRFS in alternative donor hematopoietic cell transplantation for pediatric patients with acute leukemia
Clinical Trials & Observations
Rohtesh S. Mehta,Shernan G. Holtan,Tao Wang,Michael T. Hemmer,Stephen R. Spellman,Mukta Arora,Daniel R. Couriel,Amin M. Alousi,Joseph Pidala,Hisham Abdel-Azim,Ibrahim Ahmed,Mahmoud Aljurf,Medhat Askar,Jeffery J. Auletta,Vijaya Bhatt,Christopher Bredeson,Saurabh Chhabra,Shahinaz Gadalla,James Gajewski,Robert Peter Gale,Usama Gergis,Peiman Hematti,Gerhard C. Hildebrandt,Yoshihiro Inamoto,Carrie Kitko,Pooja Khandelwal,Margaret L. MacMillan,Navneet Majhail,David I. Marks,Parinda Mehta,Taiga Nishihori,Richard F. Olsson,Attaphol Pawarode,Miguel Angel Diaz,Tim Prestidge,Muna Qayed,Hemalatha Rangarajan,Olle Ringden,Ayman Saad,Bipin N. Savani,Sachiko Seo,Ami Shah,Niketa Shah,Kirk R. Schultz,Melhem Solh,Thomas Spitzer,Jeffrey Szer,Takanori Teshima,Leo F. Verdonck,Kirsten M. Williams,Baldeep Wirk,John Wagner,Jean A. Yared,Daniel J. Weisdorf
View Articletitled, GRFS and CRFS in alternative donor hematopoietic cell transplantation for pediatric patients with acute leukemia
Supplemental data
  • Cover Image

    Cover Image

    issue cover

    COVER FIGURE
    Definitive involved-site radiation therapy administered for stage IA nodular lymphocyte-predominant Hodgkin lymphoma of the right side of the neck. Lt, left; Rt, right. See the article by Pinnix et al.

  • PDF Icon PDF LinkFront Matter
  • PDF Icon PDF LinkEditorial Board
All Issues

Advertisement intended for health care professionals

Time to revisit reduced-dose radiotherapy for PCNSL?
Lin A, Brown S, Chinapen S, et al. Patterns of CMV infection after letermovir withdrawal in recipients of posttransplant cyclophosphamide–based transplant. Blood Adv. 2023;7(23):7153-7160.
Jalink M, Jacobs CF, Khwaja J, et al. Daratumumab monotherapy in refractory warm autoimmune hemolytic anemia and cold agglutinin disease. Blood Adv. 2024;8(11):2622-2634.
Epigenetic features support the diagnosis of B-cell prolymphocytic leukemia and identify 2 clinicobiological subtypes
Retreatment of multiple myeloma with previously refractory drugs

Advertisement intended for health care professionals

Advertisement intended for health care professionals

  • American Society of Hematology
  • 2021 L Street NW, Suite 900
  • Washington, DC 20036
  • TEL +1 202-776-0544
  • FAX +1 202-776-0545

ASH Publications

American Society of Hematology

Copyright 2024 by American Society of Hematology
 
Close Modal
This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal

Advertisement intended for health care professionals